Year: 2008
Type: article
Abstract: Type I interferons (IFN-alpha/beta) are essential for immune defense against viruses and induced through the actions of the cytoplasmic helicases, RIG-I and MDA5, and their downstream adaptor molecule IPS-1. TRAF6 and the downstream kinase TAK1 have been shown to be essential for the production of proinflammatory cytokines through the TLR/MyD88/TRIF pathway. Although binding of TRAF6 with IPS-1 has been demonstrated, the role of the TRAF6 pathway in IFN-alpha/beta production has not been fully understood. Here, we demonstrate that TRAF6 is critical for IFN-alpha/beta induction in response to viral infection and intracellular double-stranded RNA, poly(I:C). Activation of NF-kappaB, JNK, and p38, but not IRF3, was impaired in TRAF6-deficient mouse embryo fibroblasts in response to vesicular stomatitis virus and poly(I:C). However, TAK1 was not required for IFN-beta induction in this process, since normal IFN-alpha/beta production was observed in TAK1-deficient mouse embryo fibroblasts. Instead, another MAP3K, MEKK1, was important for the activation of the IFN-beta promoter in response to poly(I:C). Forced expression of MEKK1 in combination with IRF3 was sufficient for the induction of IFN-beta, whereas suppression of MEKK1 expression by small interfering RNA inhibited the induction of IFN-beta by poly(I:C). These data suggest that IPS-1 requires TRAF6 and MEKK1 to activate NF-kappaB and mitogen-activated protein kinases that are critical for the optimal induction of type I interferons.
Source: Journal of Biological Chemistry
Authors: Ryoko Yoshida, Giichi Takaesu, Hideyuki Yoshida, Fuyuki Okamoto, Tomoko Yoshioka, Yongwon Choi, Shizuo Akira, Taro Kawai, Akihiko Yoshimura, Takashi Kobayashi
Institutions: Kyushu University, Medical Institute of Bioregulation, Kyushu University, Center for Integrated Medical Research, Keio University, University of Pennsylvania, Japan Science and Technology Agency, Research Institute for Microbial Diseases, The University of Osaka, The University of Osaka, Keio University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,430
Funders: Naito Foundation, Suzuken Memorial Foundation, Takeda Science Foundation, Nakatomi Foundation, Astellas Pharma, Mochida Memorial Foundation for Medical and Pharmaceutical Research, National Institute of Biomedical Innovation, Astellas Foundation for Research on Metabolic Disorders, Princess Takamatsu Cancer Research Fund
OpenAlex ID: W2031943077
